Business Wire

MA-AVICEDA-THERAPEUTICS

16.1.2024 13:01:33 CET | Business Wire | Press release

Share
Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy

Aviceda Therapeutics, a clinical-stage biotech company focused on developing novel glyco-immune therapeutics by harnessing the body’s natural immune system to modulate inflammation by using highly selective ligands designed to have maximum specificity towards target immune cells and diseases, announced today positive topline data of Part 1 of the Phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing positive safety and efficacy outcomes which were observed at 3 months after a single dose of AVD-104.

“We are excited to see signs of significant visual & functional improvement and rapid reduction in the rate of GA lesion growth with a positive overall safety profile following a single dose of AVD-104,” explained David Callanan, M.D., Aviceda’s Chief Medical Officer and Senior Vice President. “We look forward to initiating Part 2 of SIGLEC, in which we hope to demonstrate the capability of AVD-104 to provide a meaningful improvement over therapy that is only based in complement inhibition.”

“As a company overseeing the development of a novel disease-approach to GA therapy, we are encouraged by the outcomes of Part 1 of SIGLEC, and believe that AVD-104’s dual mechanism of action, which resolves both macrophage/microglial- and complement-mediated inflammation, may lead to a paradigm shift for the treatment of GA,” Mohamed Genead, M.D., Co-founder and CEO said. “In particular, we feel that putting the brakes on both the cellular and humoral drivers of disease progression in the junctional zone, the leading edge of GA, is critical for an effective, disease-modifying treatment for GA, and the results of Part 1 of SIGLEC provide evidence that AVD-104 is effective in this regard.”

SIGLEC is a two-part Phase 2/3 clinical trial based in the United States that is designed to evaluate the safety, pharmacokinetics, and efficacy of intravitreal AVD-104 in patients with GA secondary to AMD. Part 1 of the trial, a multi-center, open-label safety and dose-escalation trial of 30 patients who received a single intravitreal injection of AVD-104 and were followed for 3 months, has now been completed.

All patients in Part 1 of the trial tolerated a single dose of AVD-104 at month 3, and no drug-related ocular or systemic severe adverse reactions were observed. A greater reduction in GA lesion progression at 3 months was seen when compared to historical standard-of-care outcomes. Significant best corrected visual acuity (BCVA) gains were observed after a single AVD-104 injection and were sustained at 3 months. Junctional zone hyperautofluorescence, an imaging biomarker of rapid disease progression, was independently graded from fundus autofluorescence imaging, and was notably decreased in eyes receiving therapeutic doses of AVD-104 during the study period.

Part 2 of the SIGLEC trial is a multi-center, double-masked, randomized, controlled trial that will evaluate the efficacy and safety of AVD-104 compared with an active comparator (avacincaptad pegol) for the treatment of GA secondary to AMD. It will enroll approximately 300 patients, who will be dosed for 12 months, with the opportunity to remain in the study for an additional 12 months. The primary endpoint will be the difference in growth rate of the GA area in treated patients versus active comparator at 12 months as measured by fundus autofluorescence. Numerous other visual functional and anatomic efficacy measures will also be explored and compared between AVD-104 and the active comparator.

Further information regarding the Phase 2/3 SIGLEC trial can be found HERE.

About Aviceda Therapeutics and AVD-104

Aviceda is a clinical-stage biotech company focused on developing novel glyco-immune therapeutics by harnessing the body’s natural immune system to modulate inflammation by using highly selective ligands designed to have maximum specificity towards target immune cells and diseases. Our lead clinical-stage ophthalmic candidate, AVD-104, was developed from our proprietary HALOS™ nanotechnology platform, is under investigation for the treatment of GA secondary to age-related macular degeneration (AMD) and diabetic macular edema. AVD-104 is a promising intravitreal glycan-coated nanoparticle with a dual mechanism of action that modulates critical inflammatory cellular and complement pathways through 1) direct inhibition of damaging phagocytic/inflammatory macrophages, resolution of neovascular VEGF-producing macrophages, and repolarization of activated microglia to their neuroprotective resolution state, and 2) inhibition of complement cascade amplification. Topline results from Part 1 of the Company’s Phase 2/3 SIGLEC trial, which is evaluating AVD-104 in patients with GA secondary to AMD, have been released. Part 2 of SIGLEC, which is a double-masked, randomized, active comparator trial, is actively enrolling patients, with topline data expected in 2024 and early 2025. Part 2 of SIGLEC will enroll approximately 300 patients across the US.

Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including oncology, immunology, neurology, and fibrosis.

Learn more about Aviceda Therapeutics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116288348/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release

Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release

Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release

Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release

With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye